Tom van der Hulle, MD
Leiden University Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tom van der Hulle, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07077161 · Cabozantinib Dose Skipping as an Alternative to Dose Reductionsdr. Tom van der Hulle · recruiting · Renal Cell Carcinoma (RCC) · principal investigator
- Ph2NCT05393791 · Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPCLeiden University Medical Center · recruiting · Prostatic Neoplasms, Castration-Resistant · principal investigator
- Ph2NCT05263245 · The Pharmacological Effects of Using Cabozantinib With a Light Breakfastdr. Tom van der Hulle · completed · Renal Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.